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Abstract
The Public Symposium of the Japanese Environmental Mutagen Society (JEMS), entitled “Regulatory Science”, was
held at the Shiba-Kyoritsu campus of Keio University, Tokyo, on May 24, 2014. The concept of regulatory science
was first proposed by Dr. Mitsuru Uchiyama in 1987 as the science that reconciles the fruits of science and
technology with the most desirable form for harmony between people and society, by making accurate
predictions, assessments, and judgments, based on evidence. However, a quarter-century later, the perception
(or attitude) of the masses towards this word appears to be diverse. The main aim of this symposium was to
provide the concerned population, including the members of JEMS, with an opportunity to rediscover the role
played by JEMS in regulatory science and to discuss the meaning and implications of regulatory science, as well as
its development in Japan. The morning session comprised six lectures, including one special lecture, which
introduced the regulatory science-related activities of the organizations closely relevant to JEMS. The afternoon
session included five lectures on the issues of regulatory science, pertinent to the Food Safety Commission of Japan
(FSCJ), which were followed by a panel discussion. This symposium highlighted the important contributions of
JEMS toward development of regulatory science in Japan, in conjunction with the many challenges to be addressed.
We believe that this symposium provided great scope for eliciting interest in regulatory science, in many members
of the audience. It would be helpful if all members of the audience, as well as the readers of this article, would
attempt to clarify the challenges presented in this symposium.
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Introduction
The term “regulatory science” is getting popular in fields
of regulation of chemicals recently. The concept of regu-
latory science was initially proposed by Dr. Mitsuru
Uchiyama in 1987 as the science that reconciles the
fruits of science and technology with the most desirable
form of harmony between people and society, by making
accurate predictions, assessments, and judgments, based
on evidence. However, a quarter-century later, the per-
ception or attitude of the masses towards this word ap-
pears to be diverse. JEMS was established approximately
40 years ago, in order to adapt to the urgent need for
the identification and evaluation of environmental muta-
gens during a period of high growth in Japan. Since
then, JEMS has made an important contribution towards
the identification and evaluation of mutagens as well as
the establishment of testing guidelines for genotoxicity
evaluation.
We wish to provide the concerned population, includ-
ing the members of JEMS, with an opportunity to redis-
cover the role played by JEMS in the development and
propagation of regulatory science, and to discuss the
meaning and implications of regulatory science, as well
as its development in Japan. Following this, experts ac-
tive in the organizations associated with the regulation
of environmental mutagens were requested to introduce
the latest proceedings in regulatory science. Further-
more, experts involved in risk assessment, mainly in the
Food Safety Commission of Japan (FSCJ), were re-
quested to present a lecture based on their experience,
regarding challenges toward the development of regula-
tory science in Japan. Past discussions regarding regula-
tory science have mostly focused on approaches toward
addressing the regulation of medical drugs, Therefore, in
this symposium, we attempted to obtain novel insights
into this discussion, from another area of concern. Food
is a complex substance composed of various chemicals
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(nutrients) with a large level of exposure, i.e., large quan-
tities of food chemicals are ingested compared to chemi-
cals comprising medical/pharmaceutical products. In
addition, food is ingested by a large proportion of the
population, whereas only a small subset of these intake
drugs/pharmaceuticals. Therefore, different approaches
and/or challenges must be applied to assure food safety,
in the context of regulatory science. Accordingly, a panel
discussion was held with the lecturers, in order to im-
prove their understanding of the challenges faced by the
regulatory science organizations in Japan. This was ac-
complished via the exchange of views and ideas with the
audience.
Summary of the presentations
Eleven experts gave lectures on the various aspects of
regulatory science in this symposium. This section pro-
vides summaries of the lectures presented by nine ex-
perts. The contents of the lectures by Drs. Takei and
Kanno are provided as short reviews in the same volume
of Genes and Environment [1, 2].
“Practice of regulatory science at the National Institute of
Health Sciences” by Dr. Tohru Kawanishi, National
Institute of Health Sciences (NIHS)
Over a quarter of a century has passed since the propos-
ition by Dr. Mitsuru Uchiyama, the former Director-
General of the NIHS, that regulatory science is the sci-
ence that reconciles the fruits of science and technology
with the most desirable form for harmony between
people and society, by making accurate predictions, as-
sessments, and judgments, based on evidence [3]. Dur-
ing this time, regulatory science has been utilized to
form the basis for research concerning the evaluation of
quality, efficacy, and safety of pharmaceuticals, biologi-
cals, medical devices, regenerating products, etc., in the
field of evaluation of medical products. In addition,
regulatory science assisted in the establishment of guide-
lines for the development and review of these products.
In the field of food safety, regulatory science has been
defined as the science that supports risk analysis, which
is used to develop an estimate of the risks to human
health and safety, identify and implement appropriate
measures for the control of these risks, and communi-
cate with stakeholders regarding the risks and the ap-
plied preventive measures. Moreover, the promotion of
regulatory science has been highlighted in the Japanese
policy papers in recent years. Dr. Kawanishi summarizes
the rationale and background behind RS development.
In addition, the regulatory science-related activities of
NIHS have been introduced.
Advanced medical technologies must be developed for
the establishment of an ultra-aging society in Japan,
where people can enjoy long and healthy lives. In order
to facilitate this, a national policy for research, devel-
opment, and promotion of medical products, and the
improvement of research and development (R&D) en-
vironments for R&D is currently being formulated. In
Japan, many ideas for the development of pharmaceuticals
have originated from academia including universities.
However, almost all of the cutting-edge medical products
are first commercialized in Europe and the United States,
resulting in a so-called drug lag and device lag in Japan.
One of the major reasons being highlighted for this is the
insufficiency in the regulatory system, including the appli-
cation for and processing of government approvals. In
order to overcome this problem, the “Japan Revitalization
Strategy (June 2013)” emphasizes the enhancement and
promotion of regulatory science, which supports the R&D
of medical products of Japanese origin. In addition, Act on
promotion of healthcare policy, which would be enforced
in the autumn of 2014, includes Article 13–2: In order to
promote science (= regulatory science) touching the ap-
propriate and rapid predicts, assessments, and judgments
of their quality, efficacy and safety on the basis of scientific
evidence on the occasion of the practical use of medical
products, the state shall (a) establish necessary organiza-
tions; (b) secure and train necessary human resource, and
improve their quality; and (c) take other measures.
Currently, the NIHS is focusing on three priority sub-
jects: 1) regulatory science research, supporting the R&D
of cutting-edge medical products, 2) regulatory science
research in order to ensure the safety of food and chemi-
cals in living environment, and 3) regulatory science that
enhances the ability to perform the required tests and
investigations in Japanese laboratories. According to the
policy described above, the divisions in the NIHS related
to medical products have initiated regulatory science re-
search in 2012 to improve the developing environment of
innovative medical products. These innovative medical
products include nano-medicines, fully engineered protein
drugs, nucleic acid drugs, gene-therapy drugs, cell-therapy
products, and tissue-engineered medical products. The
current focus of the regulatory science research is the de-
velopment of point-to-consider documents to evaluate the
quality and non-clinical safety of these products. These
documents will also summarize the conditions for the first
in-human trial, especially from the quality and non-
clinical safety evaluation standpoints. The standard
methods for the evaluation of quality, efficacy, and
safety of these products have also been developed.
“Global trends in regulatory safety assessment” by
Dr. Hajime Kojima, Japanese Center for the Validation of
Alternative Methods, Division of Pharmacology, Biological
Safety Research Center, NIHS
Recent international projects concerning regulatory safety
assessment of chemicals include Tox21 [4], ToxCast™ [5],
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SEURAT-1 [6], and ARCH-Tox [7]. Overviews of these
projects were presented at the 9th World Congress on Al-
ternatives and Animal Use in the Life Sciences (WC9) in
2014 [8], and each is expected to have an impact on future
safety assessment of chemicals.
In USA, Tox21 pools federal resources and expertise
from the Environmental Protection Agency (EPA), National
Institutes of Environmental Health Sciences/National
Toxicology Program, National Institutes of Health, Na-
tional Center for Advancing Translational Sciences, and
the Food and Drug Administration in a program that
utilizes robotics technology to screen thousands of che-
micals for potential toxicity, using screening data to pre-
dict the potential toxicity of chemicals and developing a
cost-effective approach for prioritizing the thousands of
chemicals that need toxicity testing. The Tox21 consor-
tium leverages its partners’ resources and expertise to
predict more effectively how a collection of 10,000
compounds comprising environmental chemicals and
approved drugs will affect human health and the
environment.
A major part of the EPA’s CompTox research is the
Toxicity Forecaster (ToxCast™) [5], which is a multi-year
effort launched in 2007 that uses automated chemical
screening technologies, known as high-throughput
screening assays, to expose living cells or isolated pro-
teins to chemicals. The cells or proteins are then
screened for changes in biological activity that may sug-
gest potential toxic effects and eventually potential ad-
verse health effects. These innovative methods have the
potential to limit the number of required laboratory
animal-based toxicity tests while quickly and efficiently
screening large numbers of chemicals.
In the European Union, there is an ongoing long-term
strategic initiative called the Safety Evaluation Ultimately
Replacing Animal Testing [6], or SEURAT-1, to promote
the intermediate steps that have to be taken before the
final goal can be reached. SEURAT-1 will develop know-
ledge and technology building blocks required for the
development of solutions to replace the current repeated
dose systemic toxicity in vivo testing used for the assess-
ment of human safety. The SEURAT-1 Research Initia-
tive comprises six research projects, which will run for
five years, starting on January 1, 2011. These projects
promote close cooperation toward a common goal and
combine the research efforts of over 70 European uni-
versities, public research institutes, and companies.
Collaboration between these six research projects, dis-
semination of their results, cooperation with other inter-
national research teams, and continuous updating of
research priorities will be facilitated by a related coord-
ination and support action project called “COACH”.
A project in Japan called ARCH-Tox for the Future
Chemicals Management Policy: Research and Development
of in vitro and in vivo Assays for Internationally Leading
Hazard Assessment and Test Methods is being supported
by the Ministry of Economy, Trade and Industry (METI)
[7]. This project aims to establish in vitro test methods for
speedily and efficiently assessing the endpoint of 28-day re-
peated dose toxicities, hepatotoxicity, nephrotoxicity and
neurotoxicity, and will promote close cooperation toward a
common goal and combine the research efforts of six or
more Japanese universities, public research institutes, and
companies.
Also, the OECD continues its efforts to make better
use of increased knowledge on the means by which che-
micals induce adverse effects in humans and wildlife
through Adverse Outcome Pathways (AOPs) [9]. Its ef-
forts are based on knowledge of effective tools for identi-
fying chemicals that need to be regulated. AOPs provide
insight into how chemicals induce adverse effects
through toxicity pathways and modes of action. Since
2012, the AOP Development Programme at the OECD
has been pioneering the establishment of a comprehen-
sive AOP framework for the effective use of mechanistic
information in regulatory decision-making.
As a major step forward towards this goal, joint collab-
oration between the OECD, EPA, and the European
Commission Joint Research Centre launched the Ad-
verse Outcome Pathway Knowledge Base (AOP KB).
This is a web-based platform which aims to bring to-
gether all knowledge on how chemicals can induce
adverse effects, thereby providing a focal point for AOP
development and dissemination. The first AOP KB
module is the AOP Wiki: an interactive and virtual
encyclopedia for AOP development, structured in ac-
cordance with the original OECD guidance document
and template for developing and assessing adverse out-
come pathways (Series No. 184, Series on Testing and
Assessment) [10] and the more recent Handbook for
AOP developers [11].
“Introduction of ICH and recent topics related to safety”
by Dr. Hiroshi Onodera, Pharmaceuticals and Medical
Devices Agency
The development of novel medicines must focus on pro-
viding patients with safe and effective drugs on a global
scale. The marketing of a drug necessitates the regula-
tory approval of the target country or region. However,
since the documents and/or testing protocols required
for registration may differ for each country/region, a
considerable amount of time and energy might be re-
quired, which could result in a drug lag. From the view-
point of animal welfare, it is important to avoid the
unnecessary duplication of animal testing protocols. The
International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for
Human Use (ICH) is a framework, which standardizes
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such requirements for registration, simultaneously en-
suring the approval of safe, effective, and high-quality
medicines.
The ICH combines the regulatory authorities and
pharmaceutical industries in Europe, Japan, and the US.
The ICH Steering Committee (SC) is the governing body
that oversees the harmonization activities, while the Ex-
pert Working Group (EWG) is charged with the devel-
opment of a harmonized guideline, based on a scientific
consensus among experts. The topics are divided into
four categories: quality, efficacy, safety, and multidiscip-
linary. The harmonization process is common across
categories. The submission of a concept paper to the SC
is followed by discussions, which are based on the agree-
ment of the representatives from all regions. The
harmonization process is advanced in a stepwise manner,
from step 1 (consensus building) to step 5 (implementa-
tion). Currently, 10 guidelines for quality, 16 for efficacy,
10 for safety, and 7 guidelines for multidisciplinary fields
have been harmonized (see references [12] and [13]).
The M7 guideline (genotoxic impurities) has entered the
fourth step of development in June 2014. Although this
guideline was adopted by the EU on September 25, 2014
(step 5), it is yet to be validated in the US and Japan (as
of Dec 2014). This time lapse in Japan could be because
of the work related to translation and/or ensuring
consistency with the domestic rules.
The major safety guideline currently under revision is
the S1 guideline, which deals with rodent carcinogenicity
studies for the development of human pharmaceuticals.
The major objective of this review is to address the po-
tential for elimination of the two-year rat bioassay, with-
out compromising on patient safety. The existing S1
guideline necessitates the rodent two-year bioassay,
based on the duration of exposure (>6 months, or re-
peatedly in an intermittent manner), a priori concern re-
garding the carcinogenic potential, and the clinical
indication. On the contrary, no bioassay is required
when there is sufficient evidence regarding carcinogenic
concerns in humans (an indication of the genotoxic po-
tential across species, long-term treatment using im-
mune suppressants, etc.), or the technical difficulty of
long-term administration. Instead, certain measures,
such as the limitation of drug use or caution labeling,
must be applied to reduce cancer risk in humans.
Current work on revision focuses on the prediction of
negative result of bioassays based on the histopathology
from chronic toxicology studies, and/or understanding
the mode of action that does not evoke concerns in
human. The ICH has initiated its first attempt of pro-
spective data collection for analysis. The results of the
prediction are to be compared with the outcomes of all
bioassays. Although these investigations take a consider-
able amount of time, fruitful results would be expected.
“Introduction of IWGT and recent topics” by Dr.
Yoshifumi Uno, Mitsubishi Tanabe Pharma Corporation
The International Workshop on Genotoxicity Testing
(IWGT) is a gathering of international experts from
academia, government, and industry, focusing on the
harmonization of genotoxicity testing methods and/or
strategies for genotoxicity evaluation [14]. The IWGT is
composed of working groups of topics, which are to be
discussed internationally. Therefore, a chairperson, dep-
uty chair, and rapporteur have been appointed for each
topic, and the working group is organized with the ex-
perts [14].
The first IWGT (formerly IWGTP: the IWGT Proced-
ure) was convened in Melbourne, Australia in 1993. At
the time, the study protocols for genotoxicity testing had
not been standardized globally; therefore, the study data
obtained at a certain region could not be (often) ac-
cepted at other regions. Drs. T. Sofuni, M. Hayashi, and
D. Kirkland played a central role in organizing this meet-
ing, aiming to standardize genotoxicity testing. Although
the International Conference on the Harmonization of
Technical Requirements for the Registration of Pharma-
ceuticals for Human Use (ICH) has a similar objective,
the IWGT encompasses other chemicals, in addition to
the medical drugs reviewed by the ICH. Following the
4th IWGT (2005), it has been held every 4 years, in con-
junction with the International Conference on Environ-
mental Mutagens.
The working group members of the IWGT strive to
advance focused discussions, and to derive recommenda-
tions based on a data-driven consensus [14]. All discus-
sions are open to the audience; therefore, the audiences
can also make a statement, in addition to the working
group members. The consensus and/or the issues iden-
tified in the meeting is to be published in a scientific
journal, e.g. Mutation Research [15, 16]. The most ad-
vantageous aspect of this meeting is that the discussions
are based on the latest data/knowledge including un-
published information. Consequently, the outcomes of
this discussion have been highly influential in the estab-
lishment and/or revision of the guidelines for genotoxicity
testing, such OECD or ICH. In fact, the recommendations
of the IWGT have often been used as the de facto guide-
lines for the testing of guidelines that remain to be estab-
lished or revised as applicable.
The last IWGT, held in 2013 in Foz du Iguaçu, Brazil,
focused on five subjects: comet assay, Pig-A assay, liver
micronucleus assay, detection of germ cell mutagen, and
quantitative genotoxicity risk assessment. In addition,
next generation test strategies were also discussed. Many
Japanese experts participated in all working groups, and
contributed to achieving a consensus by providing crit-
ical data. Genotoxicity testing methods and/or the vari-
ous strategies for evaluation are constantly evolving.
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Therefore, the importance of IWGT is growing, where
expert scientists discuss the relevant topics based on
the latest data, in regulatory science. The next IWGT
has been scheduled in 2017 and is to be convened in
Japan.
“Introduction of Regulatory Science Working Group in
JEMS and recent topics” by Dr. Masamitsu Honma,
Division of Genetics & Mutagenesis, Biological Safety
Research Center, NIHS
There is an increase in public concern regarding the
safety of chemicals, such as food additives, pesticides,
and industrial chemicals, used in foods and/or environ-
ment. The disaster at the Fukushima nuclear power
plant induced the terror of developing cancer or heredi-
tary diseases in the future among people. This rediscov-
ered the fear of environmental carcinogens and the
importance of ensuring the safety of chemicals in envir-
onment, among the people.
The Japanese Environmental Mutagen Society (JEMS)
was established approximately 40 years ago, in order to
adapt to the urgent need for the identification and evalu-
ation of environmental mutagens, which emerged be-
cause of the drastic changes in environment during the
period of high growth. Since then, JEMS has lead several
research projects in this field, and has made an important
contribution towards the identification and evaluation of
mutagens. In addition, JEMS has also contributed to the
establishment of the testing guidelines for genotoxicity
evaluation, which is required for the approval of various
regulations, for pharmaceuticals, pesticides, food additives,
and industrial chemicals.
JEMS members must apply the results of their re-
search or their experiences for the development of these
guidelines, in order to assure the safety of the above che-
micals based on sufficient scientific evidence, which
would lead to a better society. This activity is considered
as “regulatory science”.
The regulatory science working group of JEMS was
established in 2013. The expert JEMS members volun-
teering as a part of this group provide their comments
or data on the drafting or revision of the testing guidelines
(OECD, ICH, etc.). The initial 40 members consisted of 5
experts from universities/academia, 11 from public insti-
tutes, 9 from CROs, and 15 from the pharmaceutical/
chemical industries. With the revision or abolition of the
existing OECD genotoxicity testing guidelines, the mem-
bers of the working group often provide comments to for-
mat these to the current context [17].
A new ICH guideline, M7, has been recently estab-
lished to assess and manage the genotoxic impurities in
pharmaceuticals [18]. This guideline is believed to define
new approaches to facilitate a paradigm shift in geno-
toxicity evaluation. One such approach is the application
of the Thresholds of Toxicological Concern (TTC), in
order to determine the need for further risk assessment
of impurities with low-level exposures. The acceptable
limit of mutagenic impurity is 1.5 μg per person per day,
which is considered a negligible risk (theoretical excess
cancer risk of <1 in 100,000, over a lifetime of exposure).
This criterion is derived from risk assessment, but not
from hazard identification. Another approach is the ac-
ceptance of an in silico approach to address the muta-
genic concern. The (quantitative) structure-activity
relationship ((Q)SAR) is a powerful in silico technique
used to prioritize or screen chemicals during the devel-
opment of pharmaceuticals [19]. ICH-M7, however, con-
siders the (Q)SAR to be a regulatory test assisting in
decision making during hazard assessment. The absence
of structural alerts from two complementary (Q)SAR
methodologies (expert rule-based and statistical) would
be sufficient to conclude that the impurity is of no mu-
tagenic concern. Therefore, no further testing would be
recommended. These provisions are expected to pro-
mote the trend from hazard identification to risk assess-
ment, and from ordinary testing to intelligent system
analysis.
In conclusion, the standard of regulatory science has
been altered to adapt to the social demand of the age.
There is a lot of discussion regarding the meaning of
and need for regulatory science. However, according to
his biased opinion, regulatory science can be considered
as a “moral science”, which provides the scientific basis
for conforming to the current societal norms.
“Problems assessing food’s effect on human health” by
Dr. Naoko Koizumi, former chairperson, Food Safety
Commission of Japan
To assure food safety in Japan, the functions of risk as-
sessment and risk management are separate and con-
ducted by the Food Safety Commission of Japan (FSCJ)
and other regulatory authorities. This may not be the
best approach; there are pros and cons. One of the ad-
vantages is that hazard assessment is conducted in a
scientific and neutral manner. Nevertheless, there are
still various problems and/or challenges. From the
viewpoint of public health, she has been involved in the
assessment of food’s effect on human health. She illus-
trated the problems found in the following areas rele-
vant to risk assessment: 1) in the assessment of food’s
effect on human health, there are problems in each step
of Plan-Do-Check-Act cycle; 2) the current operation of
the FSCJ; 3) challenges in the future.
Finally she pointed out that there are many problems
and challenges for improvement of these areas. She ex-
pects her talk will inspire the people involved to in-
crease their awareness of these issues and address
these concerns.
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“Challenges for regulatory science in Japan” by Dr. Makoto
Hayashi, Public Interest Incorporated Foundation BioSafety
Research Center
“It is very easy to over- or underestimate risk, but very
hard to make a rational assessment of risk.” This com-
ment was made by Professor Torahiko Terada, a famous
novelist and scientist in physics and translated into English
by Professor Sohei Kondo. Regulatory science should
promote a rational assessment of risk. Although there
are many challenges for regulatory science, the follow-
ing are considered focus points.
1) Expand understanding of regulatory science
The first priority is to expand understanding of regula-
tory science among laypeople. He thinks understanding
the following two ideas are particularly important for ra-
tional assessment: i) Hazard vs. Risk. Many people do
not see the difference between these two words. For ex-
ample, tobacco is hazardous material. However, if you
do not smoke (i.e., no exposure), there is no risk; ii) Zero
risk. We need to understand that any activity/substance
possesses risk. Even oxygen, which is necessary for our
life, poses a risk. Therefore, “zero risk” is not possible in
reality and pursing it will result in increasing other risks.
2) Training of regulatory scientists
Risk can be considered a function of multiple factors,
including hazard, exposure, target population, and more.
There are many technical hurdles to overcome to draw
conclusions. In relation to genotoxicity, considering the
threshold is an important and difficult issue. Thus, risk
assessment comprises various steps, and the assessor
needs to review a large volume of information. However,
there is no systematic training for regulatory scientists.
Education of experts capable of risk assessment is
urgent.
3) Risk communication
Communicating the outcome of risk assessment is also
a key challenge for us. Relevant stakeholders are diverse
and include consumers, producers, risk assessors, risk
managers, and others. It is difficult to find an effective
way to communicate with all the stakeholders. Neverthe-
less, communication will determine the success or fail-
ure of the risk assessment. We need to explore better
approaches for communicating the risk.
4) New initiatives
New projects or concepts, such as Tox21, AOP,
RISK21, and Risk/Benefit analysis, have been initiated in
the field of regulatory science. These can offer break-
through approaches to overcome the challenges de-
scribed above. We need to watch the developments of
these concepts closely or be involved in the development
of such activities.
“A key issue for risk assessment: threshold on
carcinogenesis” by Dr. Shoji Fukushima, Japan Bioassay
Research Center, Japan Industrial Safety & Health
Association
In order to assess the risk associated with a carcinogen,
the carcinogenicity of the target chemical must first be
assessed. Based on an analysis of the exposure status,
the possibility of tumor occurrence (risk assessment for
carcinogenesis) can be assessed.
In general, a chemical elicits a biological response in a
dose dependent manner. The upper-limit of the range in
which no response is observed is called the threshold
level. Therefore, in general toxicity analysis, it is critical
to determine the threshold of a chemical to ensure
safety. However, this raises the question regarding the
methods for assessing carcinogenic risk. Thus far, no
threshold level has been set for the evaluation of the
safety of a carcinogen, especially that of a genotoxic car-
cinogen. However, this premise has not been scientific-
ally proven.
Therefore, the carcinogenicity of various environmen-
tal carcinogens was analyzed in rats at low dose levels,
based on the “weight of evidence” [20]. Most genotoxic
carcinogens or their metabolites covalently bind to
DNA, forming adducts that lead to mutation. The initiated
cells (mutated cells) proliferate to form pre-neoplastic le-
sions, such as GST-P positive foci, which further develop
into tumor. This sequence of events is generally observed
during chemical carcinogenesis. For example, 2-amino-3,8
dimethylimidazo[4,5-f]quinoxaline (MeIQx), which is
found in cooked fish or meat, is known to provide a posi-
tive response to the Ames test and to induce tumors in
the rat liver. Rats administered MeIQx at a wide range of
doses (0.001–100 ppm) developed a MeIQx-DNA adduct
(8-hydroxy-2′-deoxyguanosine (8-OHdG)) as an oxidative
stress marker, and the GST-P positive foci, in an increas-
ing order of dosage, in the liver. These markers did not ex-
press any detectable changes at the lowest dosage. This
finding was indicative of the existence of a no-effect level.
N-nitrosodiethylamine (DEN) is known to form in the
stomach because of the reaction between the ingested
secondary amines and nitrites. DEN also provides a posi-
tive response to the Ames test and induces tumors in
the rat liver. Big Blue rats administered with DEN for 16
weeks at a wide range of doses (0.0001–1 ppm) devel-
oped GST-P positive foci, as well as an elevated muta-
tion frequency in the lacI gene, in an increasing order of
dosage, in the liver.
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Accordingly, Dr. Fukushima and his colleagues dem-
onstrated that heterocyclic amines and/or nitrosamines,
which gave a positive response in the Ames test, had a
practical threshold level for carcinogenesis in rats.
Furthermore, an approach has been initiated by aca-
demia to evaluate the genotoxicity from a quantitative,
rather than a traditional qualitative viewpoint [21, 22].
The development of such an approach would lead to in-
novations in the risk assessment of genotoxic carcinogens.
“Comparison of Japanese and overseas risk assessment
committees” by Dr. Hiroshi Yamasaki, former Kwansei
Gakuin University
In an increasingly globalized world, it is important to es-
tablish a consensus on the international risk assessment
processes. He worked for the International Agency on
Research on Cancer (IARC), and was involved in mono-
graph meetings on the evaluation of carcinogens affect-
ing humans. Further, on a request from the USA, he also
joined the committee of the National Toxicology Pro-
gram (NTP) for the evaluation of carcinogens as a scien-
tific expert.
After returning to Japan, he had the opportunity to
watch the discussions in the Food Safety Commission of
Japan (FSCJ). Based on his experience, he compared the
approaches of the FSCJ and similar organizations
overseas (mainly the USA, Europe, and Australia) to
identify preferred organizational structures for risk
assessment.
The IARC and NTP are not organizations that address
risk assessment; these organizations are involved in haz-
ard identification. However, risk assessment begins with
the identification and evaluation of hazards. Since scien-
tific data necessary for risk assessment are also gathered
and reviewed, the process of hazard evaluation is very
important. While IARC and NTP do not address “poten-
tial” carcinogens, instead focusing on those identified by
the “weight of scientific evidence,” risk assessment needs
to evaluate the “potential” of the carcinogen through the
incorporation of various information, including exposure
to the hazardous substance and the potential genetic
susceptibility of the target population. In the USA, NTP
conducts “hazard evaluation,” while the Environmental
Protection Agency (EPA) and the Food and Drug Ad-
ministration (FDA) conduct “risk assessments.” The
FSCJ, founded ten years ago to secure food safety in
Japan, conducts both hazard evaluation and risk as-
sessment. In Europe, food risk assessment is conducted
by the British Food Standards Agency (FSA) in Eng-
land, the Federal Institute for Risk Assessment (BfR) in
Germany, and the European Food Safety Authority
(EFSA) for the European Union (EU). In Australia and
New Zealand, the Food Standards Australia New Zealand
(FSANZ) conducts risk assessment for food. From his
survey on these organizations, the differences between the
FSCJ and the overseas organizations include the following.
1) Evaluation period
The monograph meetings for the evaluation of poten-
tial human carcinogens at IARC are usually held for 7–8
days and reach a conclusion within that period. Gener-
ally, the evaluation meetings held at the NTP complete
discussion and draw a conclusion within 2–3 days. The
EFSA sets a period of 3–9 weeks from the start of evalu-
ation to a conclusion and they adhere to this schedule.
On the other hand, the FSCJ has no timeframe for
reaching a conclusion; therefore, the discussion occa-
sionally continues for a long period of time. In the case
he watched, no conclusion has been reached on a poten-
tial carcinogen in the more than 10 years since the first
discussion.
2) Data used for evaluation
As a rule, the IARC and NTP use only published sci-
entific data for evaluation, and the EFSA focuses on pub-
lished data. Meanwhile, the FSCJ, although they declare
an emphasis on published data, often use unpublished
data submitted by scientists commissioned by the gov-
ernment for evaluations.
3) Cooperation with industries
Most of the above committees, except the FSCJ, select
the members involved in the discussion from industry
scientists or consultants. In general, an industry repre-
sentative is knowledgeable about the issue and has data
to add to the discussion. In the IARC and/or NTP, a few
scientists from the industry participate in the process of
evaluation; however, they do not have the authority to
make judgments. Based on his experience, he believes
including representatives from the industry is necessary
for a fair evaluation.
Based on the differences identified above, he proposes
that the FSCJ take the following actions to improve their
risk assessment committees. First, the FSCJ needs to
separate “solution-focused” from “problem-focused” dis-
cussions to allow conclusions using publically available
scientific data to be reached by a pre-established target
deadline. Second, the FSCJ needs to cooperate with all
stakeholders, especially those from industry. Discussions
that include other stakeholders will result in a fair and
speedy evaluation.
Panel discussion
Panel members included the following five lecturers of
the symposium: Dr. Naoko Koizumi (NK), Dr. Makoto
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Hayashi (MH), Dr. Shoji Fukushima (SF), Dr. Jun Kanno
(JK), and Dr. Hiroshi Yamasaki (HY). Moderator was
Toshio Kasamatsu (TK). Details of the panel discussion
are described in the Additional file 1.
Conclusion
As many as 154 people participated in the symposium,
based on the number of leaflets distributed. The partici-
pants were asked to answer a questionnaire; 57 answers
were received in total from JEMS members (19; 33 %),
and non-members (30; 53 %), and people who left no re-
cords (8; 14 %). This indicated that over half the partici-
pants were non-JEMS members. The feedback received
included favorable (“Symposium was very interesting”,
“It was very helpful to obtain an overview of regulatory
science”, and “It was great to understand the difference
between risk assessment and risk management”), as well
unfavorable/critical (“Symposium did not fully focus on
regulatory science”, “There were few talks on the idea or
the standard of regulatory science”, and “Not showing
vision for the specific measures adopted by JEMS to-
wards the development of a young successor, including
the potential of JEMS itself, or what JEMS can accom-
plish by approaching the government, etc.”) comments.
An analysis of the symposium, based on the comments
presented above, revealed the following points; the lec-
tures presented the current achievements of JEMS, as
well as the challenges that remain to be addressed; the
important contribution made by JEMS towards the es-
tablishment of regulatory science was well recognized;
on the other hand, basic framework regarding the as-
sessment of genotoxicity has remained unchanged over
the past decades. Regarding the final point, the Ames
test, which was developed approximately 40 years ago,
remains to be the golden standard in genotoxicity test-
ing, despite the development and proposal of various
new testing strategies for regulatory applications. Upon
obtaining a positive result in the Ames test, the tested
chemical would be treated as a mutagen. Alleged geno-
toxicity and/or carcinogenicity concerns have led to the
setting of a high standard for regulatory decision mak-
ing, regarding the safety of chemicals. Nevertheless,
TTC, a novel concept explained by Dr. Honma, and the
genotoxicity threshold model proposed by Dr. Fukushima
et al., might provide the vital clue towards establishing
novel frameworks for regulatory science.
The panel discussion also revealed important chal-
lenges to be overcome for the development of regulatory
science in Japan. These include: 1) the lack of an estab-
lished approach for the evaluation of safety of entire
food, 2) the urgent need for development and appoint-
ment of young successors, and 3) the involvement of in-
dustry representative in evaluation, etc. There is no
simple solution detailing the contribution of JEMS
towards addressing these challenges, However, JEMS
should be able to attractively present young scientists
with challenges worth working on, as well as support
their ideas for the establishment of new standards for
regulatory science.
As the coordinators of the symposium, we are also
attempting to contrive better ways to communicate the
concept of regulatory science. Nevertheless, we believe it
was a great opportunity to elicit interest in many mem-
bers of the audience regarding regulatory science. As ex-
plained in the Introduction, the major objective of this
symposium was to rediscover the role played by JEMS in
the development and propagation of regulatory science,
and to provide the people (including JEMS members)
with an opportunity to discuss the meaning of regulatory
science, and strategies for its development in Japan.
Although there are several concepts clarifying the
above issues, it would be helpful if all members of
the audience, as well as the readers of this article,
would attempt to clarify these points.
Based on a request in the questionnaire, the presenta-
tion materials of the lecturers have been up-loaded, with
due permission, on the JEMS homepage <http://www.j-
ems.org/symposium/2014symposium.html>. We hope
that this would help understand regulatory science.
Additional file
Additional file 1: Panel discussion (JEMS symposium 2014).
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